Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14;44(1):429.
doi: 10.1007/s10792-024-03354-9.

Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome

Pietro Paolo Saba #  1 , Alessandro Feo #  1 , Luca Pagano  2 , Paolo Vinciguerra  1   3 , Riccardo Vinciguerra  4
Affiliations

Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome

Pietro Paolo Saba et al. Int Ophthalmol. .

Abstract

Purpose: To assess the short and mid-term outcomes of epithelium-off (epi-off) corneal collagen cross-linking using Riboflavin with Vitamin E TPGS (Epi-off Ribocross® CXL) for progressive keratoconus (KC).

Design: Retrospective, single-center non-comparative interventional study.

Methods: Patients with progressive keratoconus who underwent CXL using (Epi-off Ribocross® CXL) from May 2021 to May 2022 who completed at least 12 months of follow-up in Humanitas Clinical and Research Center, Rozzano, Milan, Italy. Corrected distance visual acuity with spectable (CDVA), tomographic parameters (Belin ABCD) and topographic parameters were evaluated at baseline and at last follow up.

Results: Twenty eyes of twenty patients fulfilled inclusion criteria. CDVA remained stable at last follow up (0.88 ± 0.19 from 0.83 ± 0.21, p = 0.45) with a significant reduction in cylinder (1.97 ± 1.69 from 2.78 ± 2.19, p = 0.03). Kmax significantly improved from 53.18D ± 6.32 to 50.96 ± 5.3D (p = 0.005). At the last follow up, no case of progression was noted.

Conclusions: Epi-off Ribocross® CXL proved to be a safe treatment for progressive KC, with a stabilization of all cases at the one year follow up. Further studies are needed to confirm long-term stability.

Keywords: Cross-linking; Epi-off; Keratoconus; Ribocross; Vitamin E TPGS.

PubMed Disclaimer

Conflict of interest statement

Declarations Conflicts of interest The authors declare no competing interests. Ethical approval This study was performed in line with the principles of the Declaration of Helsinki. Informed consent Informed consent, including consent for publication of the images, was obtained from the patients.

Similar articles

See all similar articles

References

    1. Santodomingo-Rubido J, Carracedo G, Suzaki A, Villa-Collar C, Vincent SJ, Wolffsohn JS (2022) Keratoconus: an updated review. Cont Lens Anterior Eye 45(3):101559. https://doi.org/10.1016/j.clae.2021.101559 - DOI - PubMed
    1. Romano V, Vinciguerra R, Arbabi EM et al (2018) Progression of keratoconus in patients while awaiting corneal cross-linking: a prospective Cclinical study. J Refract Surg 34(3):177–180. https://doi.org/10.3928/1081597X-20180104-01 - DOI - PubMed
    1. Wollensak G, Spoerl E, Seiler T (2003) Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg 29(9):1780–1785. https://doi.org/10.1016/s0886-3350(03)00407-3 - DOI - PubMed
    1. Zweifel SA, Spaide RF, Curcio CA et al (2010) Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 117(2):303-312.e1. https://doi.org/10.1016/j.ophtha.2009.07.014 - DOI - PubMed
    1. Vinciguerra P, Montericcio A, Catania F et al (2021) New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking. Int Ophthalmol 41(5):1909–1916. https://doi.org/10.1007/s10792-021-01713-4 - DOI - PubMed

MeSH terms

LinkOut - more resources